Free tool
FAERS Monitor: Javadin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220256 or its brand name (Javadin, Clonidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3
Serious
1
33% of reports
Hospitalization
0
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1
- product prescribing issue1
- product primary packaging issue1
- product taste abnormal1
- product use in unapproved indication1
- product use issue1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product primary packaging issue | 1 | 63225.7 | 12624.0 | 15,664 |
| product taste abnormal | 1 | 517.8 | 104.5 | 129 |
| product prescribing issue | 1 | 321.8 | 65.0 | 80 |
| product use issue | 1 | 37.3 | 7.5 | 8 |
| product use in unapproved indication | 1 | 28.3 | 5.7 | 6 |
| death | 1 | 8.1 | 1.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.